AmCad BioMed Corporation (4188) AI Stock Analysis

AmCad BioMed Corporation

(TPEx:4188)

Select Model

Rating:43Neutral

Price Target:TWD 14.00▲(4.09% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by severe operating losses, declining revenue and margins, and persistent negative cash flow. Mixed technical indicators and unfavorable valuation provide limited support, while the strong balance sheet prevents an even lower assessment.

Positive Factors

Conservative Balance SheetVery low leverage gives AmCad BioMed greater financial flexibility than a heavily indebted business, allowing it to absorb ongoing losses without immediate debt pressure. The substantial equity base can also support continued investment in clinical software and AI development while management works toward profitability.

Negative Factors

Persistent UnprofitabilityRecurring losses across six years show that the business has not yet converted its technology and clinical software activities into sustainable earnings. Continued negative EBIT and EBITDA reduce internal funding capacity, constrain strategic flexibility, and make a durable improvement in operating execution essential.

AmCad BioMed Corporation (4188) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 845.49M
Dividend Yield: ―
Average Volume (3M): 340.10K
Price to Earnings (P/E): -15.0
Beta (1Y): 0.53
Revenue Growth: -39.87%
EPS Growth: -14.87%
Country: TW
Employees: 69,576
Sector: General
Sector Strength: 55
Industry: Software - Application

AmCad BioMed Corporation Business Overview & Revenue Model

Company Description

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD de...

AmCad BioMed Corporation Financial Statement Overview

Summary

Severe revenue decline, shrinking gross margin, persistent losses, and negative operating and free cash flow outweigh the strong, lightly leveraged balance sheet.

Income Statement

8Very Negative

Balance Sheet

78Positive

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.60M	30.44M	53.10M	65.26M	61.63M	85.79M
Gross Profit	10.33M	10.02M	32.93M	41.02M	38.05M	60.66M
EBITDA	-66.58M	-55.52M	-34.41M	-25.56M	-36.60M	-8.46M
Net Income	-56.98M	-55.72M	-50.58M	-45.31M	-53.49M	-25.54M
Balance Sheet
Total Assets	617.38M	622.70M	694.87M	512.65M	553.86M	615.75M
Cash, Cash Equivalents and Short-Term Investments	341.88M	371.22M	365.71M	287.27M	330.84M	371.05M
Total Debt	13.35M	4.75M	10.87M	14.50M	10.49M	14.80M
Total Liabilities	29.33M	21.88M	31.16M	34.70M	34.08M	36.72M
Stockholders Equity	515.55M	521.42M	568.65M	380.58M	424.58M	482.98M
Cash Flow
Free Cash Flow	-47.43M	-47.44M	-54.90M	-41.89M	-34.81M	-41.30M
Operating Cash Flow	-47.31M	-47.06M	-51.85M	-41.60M	-34.19M	-38.97M
Investing Cash Flow	58.21M	58.93M	-185.43M	27.31M	27.14M	49.18M
Financing Cash Flow	-4.76M	-5.02M	225.38M	-3.10M	-4.42M	-11.35M

AmCad BioMed Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4188 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4188	43Neutral	TWD 867.66M	-15.00	―	―	-39.87%	-14.87%
TW:4171	40Underperform	TWD 896.99M	-40.49	―	―	11.99%	84.94%

* General Sector Average

Performance Comparison

TW:4188 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4188	AmCad BioMed Corporation	13.45	-2.45	-15.41%
TW:4171	GeneReach Biotechnology Corp.	15.50	-5.50	-26.19%
TW:6810	Bio Preventive Medicine Corp.	22.75	-1.75	-7.14%
TW:6850	Bioptic Inc.	27.65	-12.75	-31.55%
TW:6879	Tci Gene Inc.	35.50	-3.65	-9.32%
TW:7725	LabTurbo Biotech Corporation	21.00	-1.81	-7.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

AmCad BioMed Corporation AI Stock Analysis